Following the successful completion of the merger, which remains subject to final closing procedures, a series of important changes will be implemented for investors. The common stock, currently trading under the COEP ticker, will undergo a transformation. This includes a new company name, a fresh trading symbol, and an updated CUSIP number to reflect the consolidated entity.
Simultaneously, the warrants associated with Coeptis Therapeutics (COEPW) will be suspended from trading. These changes are scheduled to become effective on Monday, 27th April 2026, signaling the official launch of the combined company under its new identity on the stock exchange.
The newly combined company will operate under the name Z Squared Inc. and its common stock will trade under the new symbol ZSQR. The CUSIP number, a unique identifier for financial instruments, will also be updated from 19207A207 to 98878K108. These identifier changes are crucial for market participants and will take effect from the marketplace effective date, Monday, 27th April 2026.
This merger represents a strategic move for both Coeptis Therapeutics and Z Squared, aiming to leverage synergistic opportunities and enhance shareholder value. The listing on the Nasdaq Global Market will provide the combined entity with increased visibility, access to a broader investor base, and potentially greater liquidity, positioning it for future growth and innovation within its sector.
Investors holding Coeptis Therapeutics common stock and warrants should take note of these impending changes. The suspension of COEPW warrants from trading will impact their portfolio, while the new ticker and company name for the common stock will be relevant for all future trading activities. It is advisable for shareholders to consult with their financial advisors regarding the implications of these corporate actions.
TradeRadarNews will continue to monitor the progress of this business combination and provide further updates as they become available. The successful integration of Coeptis Therapeutics and Z Squared is expected to create a robust new player in the market, with its journey on the Nasdaq Global Market commencing next week.
